Pathologic Stage III Cutaneous Melanoma AJCC v8

general

Stage IIIB includes: (T0, N1b, N1c, M0); (T1a/b-T2a, N1b/c or N2b, M0); (T2b/T3a, N1a-N2b, M0). T0: No evidence of primary tumor (e.g., unknown primary or completely regressed melanoma). Thickness: Not applicable. Ulceration status: Not applicable. T1a: Tumor measuring less than 0.8 mm in thickness. Ulceration status: Without ulceration. T1b: Tumor measuring less than 0.8 mm in thickness with ulceration, or 0.8-1.0 mm with or without ulceration. T2a: Tumor measuring more than 1.0 and equal to or

22

Centers

24

Active Trials

$4.2B

Cancer Funding

Specific Cancer Types(1)

NameCenters
Melanoma Stage IIIC19

Top Centers for Pathologic Stage III Cutaneous Melanoma AJCC v8(22)

Ranked by research excellence score (trials · grants · publications). Methodology →

#CenterScore
1
NCI Comprehensive
Active Research Program
63.6
2
NCI Comprehensive
Active Research Program
63.6
3
NCI Comprehensive
Active Research Program
63.6
4
Active Research Program
63.6
5
Active Research Program
63.6
6
NCI Comprehensive
41.1
741.1
8
NCI Comprehensive
9
NCI Comprehensive
10
11
NCI Comprehensive
12
NCI Comprehensive
13
14
NCI Comprehensive
15
NCI Comprehensive
16
NCI Comprehensive
17
Rutgers Cancer InstituteNew Brunswick, NJ
NCI Comprehensive
18
Fox Chase Cancer CenterPhiladelphia, PA
NCI Comprehensive
19
20
21
22

Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →